Table 3.

The latency patterns of EBV-associated cancers.

Variable	Latency I	Latency II	Latency III
EBER	Positive	Positive	Positive
EBNA1	Positive	Positive	Positive
EBNA2	Negative	Negative	Positive
LMP1	Negative	Positive	Positive
Histological type	Burkitt lymphoma EBV+ gastric cancer	CHL (50%) EBV+DLBCL (common) CAEBV/HVLPD/SMBA PEL ENKTL NPC AITL OI-LPD (common)	EBV+SMT EBV+DLBCL (uncommon) LYG PAL/FA-DLBCL PTLD OI-LPD (uncommon)

Abbreviations: AITL, Angioimmunoblastic T-cell lymphoma; CAEBV, Chronic active HBV infection of T- and NK-cell type, systemic form; CHL, Classical Hodgkin lymphoma; EBER, EBV-encoded small RNA; EBNA, EBV-encoded nuclear antigen; EBV+DLBCL, EBV-positive diffuse large cell B-cell lymphoma, not otherwise specified (NOS); EBV+SMT, EBV-associated smooth muscle tumor; ENKTL, Extranodal NK/T-cell lymphoma, nasal type; FA-DLBCL, Fibrin-associated diffuse large cell B-cell lymphoma; HVLPD, Hydroa vacciniforme-like lymphoproliferative disorders; LMP, Late membrane protein; LYG, Lymphomatoid granulomatosis; NPC, Nasopharyngeal carcinoma; OI-LPD, Other iatrogenic lymphoproliferative disorder; PAL, Pyotholax-associated lymphoma; PEL, Primary effusion lymphoma; SMBA, severe mosquito bite allergy; PTLD, Post-transplant lymphoproliferative disorders.